TD Securities has issued a buy rating for Establishment Labs, highlighting that the popularity of GLP-1 drugs, which aid in weight loss, is contributing to a surge in breast augmentation procedures. Analyst Joshua Jennings noted that U.S. breast augmentation growth accelerated by 10% due to the launch of the Motiva breast implant line and the impact of GLP-1s.
A recent poll indicated that approximately one in eight adults in the U.S. are using GLP-1 medications like Ozempic, reflecting a growing trend. The American Society of Plastic Surgeons reported a 7% growth in the U.S. cosmetic surgery market in 2025, with breast augmentation volumes increasing by 11%.
Additionally, procedures associated with post-weight loss patients saw over a 20% growth last year. Jennings views this trend as a positive sign for Establishment Labs, especially with the limited launch of their Preservé implant line in 2025, which is expected to further expand their market presence.
The consensus among analysts is bullish, with all nine covering Establishment Labs rating it as a buy or strong buy. Following this optimistic outlook, shares of Establishment Labs rose nearly 4%, reducing their year-to-date losses to about 1%